Download PDF
Thromb Haemost 1997; 77(03): 498-503
DOI: 10.1055/s-0038-1655996
Coagulation
Schattauer GmbH Stuttgart

The Ability of Thrombin Inhibitors to Reduce the Thrombin Activity Generated in Plasma on Extrinsic and Intrinsic Activation

D Prasa
1   The Zentrum für Vaskuläre Biologie und Medizin, Klinikum der Friedrich-Schiller-Universität Jena, Germany
,
L Svendsen
2   The Pentapharm Ltd., Basel, Switzerland
,
J Stürzebecher
1   The Zentrum für Vaskuläre Biologie und Medizin, Klinikum der Friedrich-Schiller-Universität Jena, Germany
› Author Affiliations
Further Information

Publication History

Received 09 May 1996

Accepted after resubmission 15 November 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a thrombin generation test with continuous registration of thrombin activity in plasma we studied the ability of a variety of thrombin inhibitors of different type and mechanism of action to influence the activity of thrombin after activation of the coagulation system. Depending on the inhibitor, the peak of thrombin activity is delayed and/or reduced.

By blocking the active site of generated thrombin inhibitors cause a concentration dependent reduction of the thrombin peak and inhibit feed-back reactions of thrombin resulting in a delay of thrombin generation. Highly potent synthetic active-site directed inhibitors (Ki ≤ 20 nM) reduce the thrombin activity formed in plasma after extrinsic or intrinsic activation with the same efficiency (IC50 0.1 - 0.6 μM) as hirudin. The delay and reduction of thrombin generation by inhibitors of the anion-binding exosite 1 of thrombin is only attributed to an inhibition of feed-back reactions of thrombin. For a 50% reduction of thrombin activity in plasma by this type of inhibitors relatively high concentrations were determined.

 

  • References

  • 1 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Walz DA, Anderson GF, Ciaglowski RE, Aiken M, Fenton IIJW. Thrombin-elicited contractile responses of aortic smooth muscle. Proc Soc Exp Biol Med 1985; 180: 518-526
    CrossrefPubMedGoogle Scholar
  • 3 Scully MF. Kinetic considerations on the physiologic control of thrombin and factor Xa. Semin Thromb Hemost 1992; 18: 218-223
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Stone SR, Tapparelli C. Thrombin inhibitors as antithrombotic agents:the importance of rapid inhibition. J Enzyme Inhibition 1995; 9: 3-15
    PubMedGoogle Scholar
  • 5 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone. Proc Natl Acad Sci USA 1988; 85: 3184-3188
    CrossrefPubMedGoogle Scholar
  • 6 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-1012
    PubMedGoogle Scholar
  • 7 Kelly AB, Hanson SR, Dunwiddie CT, Harker LA. Safe lasting interruption of arterial thrombosis by transient intravenous administration of tick anticoagulant peptide TAP. Circulation 1992; 86 suppl: 411
    PubMedGoogle Scholar
  • 8 Lindahl AK, Wildgoose P, Lumsden AB, Allen R, Kelly AB, Harker LA, Hanson SR. Active-site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons. Circulation. 1993; 88 suppl: 417
    PubMedGoogle Scholar
  • 9 Gast A, Tschopp TB, Baumgartner HR. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb 1994; 14: 1466-1474
    CrossrefPubMedGoogle Scholar
  • 10 Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994; 74: 1-23
    CrossrefPubMedGoogle Scholar
  • 11 Bajusz S, Barabas E, Tolnay P, Szell E, Bagdy D. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int J Pept Protein Res 1978; 12: 217-221
    PubMedGoogle Scholar
  • 12 Bagdy D, Barabas E, Bajusz S, Szell E, Szabo G, Valko I. Studies on the anticoagulant effect and pharmacokinetics of N-methyl-D-Phe-Pro-Arg-H (GYKI 14 766). Thromb Haemost 1989; 62: 535
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Kettner C, Shaw E. D-Phe-Pro-Arg-CH2Cl – a selective affinity label for thrombin. Thromb Res 1979; 14: 969-973
    CrossrefPubMedGoogle Scholar
  • 14 Neises B, Tamus C. Thrombin inhibition by the tripeptide trifluoromethyl ketone D-Phe-Pro-Arg-CF3(MDL 73756). Thromb Haemost 1991; 65: 2155
    PubMedGoogle Scholar
  • 15 Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-18297
    PubMedGoogle Scholar
  • 16 Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative Nr, 805:the importance of the stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446
    CrossrefPubMedGoogle Scholar
  • 17 Stürzebecher J, Markwardt F, Voigt B, Wagner G, Walsmann P. Cyclic amides of Nαarylsulfonyl-aminoacylated 4-amidinophenylalanine – tight binding inhibitors of thrombin. Thromb Res 1983; 29: 635-642
    CrossrefPubMedGoogle Scholar
  • 18 Stürzebecher J, Hauptmann J, Prasa D, Wikström P, Vieweg H. Synthesis and structure-activity relationships of potent thrombin inhibitors derived from piperazides of 3-amidinophenylalanine. J Med Chem. 1997. in press
    Google Scholar
  • 19 Hilpert K, Ackermann J, Banner DW, Gast A, Gubemator K, Schmid G, Tschopp TB, van de Waterbeemd H. The development of potent and highly selective thrombin inhibitors. Europ J Med Chem 1995; 30 Suppl: 132S-138S
    PubMedGoogle Scholar
  • 20 Dickneite G, Seiffge D, Diehl KH, Reers M, Czech J, Weinmann E, Hoffmann D, Stüber W. Pharmacological characterization of a new 4-ami-dinophenylalanine thrombin inhibitor (CRC 220). Thromb Res 1995; 77: 357-368
    CrossrefPubMedGoogle Scholar
  • 21 Mack H, Pfeiffer T, Homberger W, Böhm HJ, Höffken HW. Design synthesis and biological activity of novel rigid amidinophenylalanine derivatives as inhibitors of thrombin. J Enzyme Inhibition 1995; 9: 73-86
    PubMedGoogle Scholar
  • 22 Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin:identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry 1988; 27: 8170-8173
    CrossrefPubMedGoogle Scholar
  • 23 Naski MC, Fenton JW, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. J Biol Chem 1990; 265: 13484-13489
    PubMedGoogle Scholar
  • 24 Payne MH, Krstenansky JL, Yates MT, Mao SJT. Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides. J Med Chem 1991; 34: 1184-1187
    CrossrefPubMedGoogle Scholar
  • 25 Homberger W, Rübsamen K, Laux V, Schwarz M, Bernard H. Antithrombin and antithrombotic properties of a new decapeptide thrombin exosite inhibitor (LU 58463) – comparison with hirudin. Thromb Haemost 1993; 69: 1300
    PubMedGoogle Scholar
  • 26 Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton IJW. Design and characterization of hirulogs:A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7107
    CrossrefPubMedGoogle Scholar
  • 27 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Hemker HC, Béguin S. Mode of action of heparin and related drugs. Semin Thromb Hemost 1991; (Suppl. 01) 29-34
    PubMedGoogle Scholar
  • 30 Béguin S, Wielders S, Lormeau J-C, Hemker HC. The mode of action of CY216 and CY222 in plasma. Thromb Haemost 1992; 67: 33-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Lormeau J-C, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin low molecular weight heparin and the synthetic AT III-binding pentasaccharide. Thromb Haemost 1993; 69: 152-156
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood – the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Verhallen PFJ, Gehrmann G, Prasa D, Stiirzebecher J. Measurement of thrombin generation in human plasma by two different methods (subsample/continuous):characterization of different anticoagulants. Thromb Haemost 1995; 73: 1247
    PubMedGoogle Scholar
  • 34 Gast A, Tschopp TB. Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240) recombinant hirudin and heparin in human plasma. Blood Coag Fibrinol 1995; 6: 553-560
    CrossrefPubMedGoogle Scholar
  • 35 Walsmann P. Über die Reinigung von Thrombinpräparaten. Pharmazie 1968; 23: 401-402
    PubMedGoogle Scholar
  • 36 Richter P, Wagner G. Synthesen von 4-Amidinophenylbrenztraubensäure (APPA). Teil 1. Pharmazie 1973; 28: 514-519
    PubMedGoogle Scholar
  • 37 Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-171
    CrossrefPubMedGoogle Scholar
  • 38 Henderson PJF. A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interaction with tightly bound inhibitors. Biochem J 1972; 127: 321-333
    CrossrefPubMedGoogle Scholar
  • 39 Neises B. The synthesis and anticoagulant activity of novel peptidylfluoroalkanes. Adv Exp Med Biol 1993; 340: 185-188
    PubMedGoogle Scholar
  • 40 Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptides of arginine chloromethyl ketones. Methods Enzymol 1981; 80: 826-842
    PubMedGoogle Scholar
  • 41 Deadman J, Claeson G, Scully MF. Structure/function aspects of neutral PI residue peptide inhibitors of thrombin. J Enzyme Inhibition 1995; 9: 29-41
    PubMedGoogle Scholar
  • 42 Odake S, Kam C-M, Powers JC. Inhibition of thrombin by arginine-containing peptide chloromethyl ketones and bis chloromethyl ketone-albumin conjugates. J Enzyme Inhibition 1995; 9: 17-27
    PubMedGoogle Scholar
  • 43 Oleksyszyn J, Boduszek B, Kam C-M, Powers JC. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. J Med Chem 1994; 37: 226-231
    CrossrefPubMedGoogle Scholar
  • 44 Tapparelli C, Metternich R, Ehrhardt C, Zurini M, Claeson G, Scully MF, Stone SR. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268: 4734-4741
    PubMedGoogle Scholar
  • 45 Fusetani N, Nakao Y, Matsunaga S. Nazumamide A a thrombin-inhibitory tetrapeptide from a marine sponge theonella sp. Tetrahedron Lett 1991; 32: 7073-7074
    CrossrefPubMedGoogle Scholar
  • 46 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
    PubMedGoogle Scholar
  • 47 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024
    PubMedGoogle Scholar
  • 48 Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanism for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann N Y Acad Sci 1986; 485: 41-55
    CrossrefPubMedGoogle Scholar
  • 49 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feed-back reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-588
    CrossrefPubMedGoogle Scholar
  • 50 Markwardt F, Hoffmann J, Körbs E. The influence of synthetic thrombin inhibitors on the thrombin-antithrombin reaction. Thromb Res 1973; 2: 343-348
    CrossrefPubMedGoogle Scholar
  • 51 Griffith MJ, Kingdon HS, Lundblad RL. Inhibition of the heparin-anti-thrombin III/thrombin reaction by active site blocked-thrombin. Biochem Biophys Res Commun 1979; 87: 686-692
    CrossrefPubMedGoogle Scholar
  • 52 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8698
    PubMedGoogle Scholar
  • 53 Krstenansky JL, Owen TJ, Yates MT, Mao SJT. The C-terminal binding domain of hirullin PI8 – Antithrombin activity and comparison to hirudin peptides. FEBS Lett. 1990; 269: 425-429
    PubMedGoogle Scholar